Shelton Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Shelton Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.03M	Buy	+6,112	New	+$907K	0.4%	82

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12B AUM

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Shelton Wealth Management's NBIX Position: Q2 2026 in Review

Shelton Wealth Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 6,112 shares worth $1.03M. The stake represents 0.4% of the portfolio and ranks #82 among its holdings.

84 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Shelton Wealth Management held 6,112 shares of Neurocrine Biosciences worth $1.03M as of Q2 2026.
Neurocrine Biosciences was a new Shelton Wealth Management position in Q2 2026.
Neurocrine Biosciences made up 0.4% of Shelton Wealth Management's portfolio in Q2 2026, its #82 holding.
84 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Shelton Wealth Management's 13F filing for Q2 2026, filed 13 Jul 2026.